23 F. Supp. 3d 748
W.D. Tex.2014Background
- Mission owns the '247 patent covering a dual iron nutritional supplement and related methods; Virtus markets Natalvirt products claimed to be equivalents; the dispute centers on false advertising and unfair competition under the Lanham Act and Texas law; both sides agree the products are interstate commerce and FDCA-regulated; Mission contends Virtus markets are generics that are not pharmaceutically or bioequivalently substitutable; Virtus argues both product lines are dietary supplements or non-generic, non-drug products and labels comply with applicable regulations; a prior schedule and mediation history framed ongoing proceedings.
- Mission sells CitraNatal Assure, CitraNatal 90 DHA, Ferralet 90 and Virtus sells Natalvirt CA, Natalvirt 90 DHA, Natalvirt FLT; Virtus’s products contain ferrous gluconate encapsulated in slow-dissolving matrices, contrasting with Mission’s fast-dissolving iron; both products are regulated under FDCA/DSHEA but have contested regulatory status (drug vs dietary supplement); Mission alleges Virtus falsely markets Natalvirt as generic equivalents enabling substitution; Virtus contends its labeling is accurate and not misleading.
- The parties underwent stays and repeated briefing on cross-motions for summary judgment; Virtus filed a motion for partial summary judgment on false advertising and unfair competition claims, Mission filed responses and cross-motions on patent infringement; the magistrate judge recommended denying Virtus’s motion; the district court adopted and accepted the recommendation, denying Virtus’s partial summary judgment.
- The court’s analysis referenced Healthpoint framework (FDA definitions of generic and bioequivalence) and prior Fifth Circuit standards; the decision rests on whether material facts about equivalence and representation are disputed, requiring trial for resolution of factual issues.
- The procedural posture involves cross-motions for partial summary judgment on noninfringement and false advertising, with the court ultimately denying Virtus’s motion and denying judgment as a matter of law on the false advertising/unfair competition claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Virtus’ motion for partial summary judgment should be denied | Mission argues genuine issues exist on equivalence and labeling claims | Virtus asserts labels comply with DSHEA/FDCA and products are not drug equivalents | Denied; genuine issues of material fact remain. |
| Whether Virtus’ generic-equivalent advertising is literally false | Mission contends claims mislabel Virtus products as generics/substitutes | Virtus argues no literal falsehood given regulatory definitions and identical ingredients | Denied; factual disputes persist over equivalence and consumer impact. |
| Whether FDA definitions govern the Lanham Act issues or a separate market standard should apply | Mission urges FDA terms of art govern the analysis | Virtus argues FDA terms are not controlling for dietary supplements | Denied; issues of fact remain regarding regulatory status and equivalence. |
| Whether there is a likelihood of confusion under the Lanham Act and Texas unfair competition | Mission asserts substitution and branding imply equivalence | Virtus contends no misleading claim given labeling accuracy | Genuine issues of material fact exist; not appropriate for summary judgment. |
Key Cases Cited
- Kreim-erman v. Casa Veerkamp, S.A. de C.V., 22 F.3d 634 (5th Cir.1994) (de novo review procedure for objections to magistrate's report)
- Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (S. Ct. 1986) (summary judgment standard: genuine dispute of material fact required)
- Pizza Hut, Inc. v. Papa John’s Int’l, Inc., 227 F.3d 489 (5th Cir.2000) (summary judgment when no genuine issues of material fact)
- Taylor Publishing Co. v. Jostens, Inc., 216 F.3d 465 (5th Cir.2000) (summary judgment standards and evidence evaluation)
- Acuna v. Brown & Root, Inc., 200 F.3d 335 (5th Cir.2000) (proper consideration of evidence and summary judgment)
- Westchester Med. Ctr. v. PRL USA Holdings, Inc., 214 F.3d 658 (5th Cir.2000) (unfair competition analysis and likelihood of confusion)